High-yield points
- Overall in children: about 63% respond and 14% become seizure-free. CM, ANT and pulvinar results don't differ significantly in pooled data .
- Match the target to the network: ANT for focal temporal or frontal epilepsy , CM for generalized epilepsy and LGS , and pulvinar for temporal and posterior networks .
- ANT targeting:
- Aim for the anteroventral ANT at the MTT junction, seen on FGATIR .
- A transventricular trajectory hits the target more reliably (84% vs 58%) .
- Good placement roughly doubles responder rates .
- CM targeting:
- See CM on MP2RAGE .
- Aim for the anterior-inferolateral parvocellular border, mean MNI about −13, −17, +1 .
- MER is inconsistent .
- Pulvinar targeting: aim for the medial pulvinar on an extraventricular trajectory. Consider SEEG sampling first .
- Safety: major complications in about 4% of children implanted for epilepsy. Watch for mood and memory effects with ANT stimulation .
Landmark papers
- SANTÉ (Fisher et al., Epilepsia 2010): randomized trial of anterior thalamic stimulation (110 adults). Median seizure reduction was 40.4% with stimulation vs 14.5% without in the blinded phase .
- ESTEL (Dalic et al., Ann Neurol 2022): randomized trial of centromedian thalamic DBS in 20 young adults with LGS. Electrographic seizures fell by at least 50% in 59% vs none of the controls; diary seizures 50% vs 22%, not significant .
Thalamic DBS is an option for children with drug-resistant epilepsy that can't be resected. The target is chosen by the seizure network:
- ANT for focal limbic (temporal and frontal) epilepsy.
- CM for generalized epilepsy and Lennox–Gastaut syndrome (LGS).
- Medial pulvinar for temporal and posterior-quadrant networks.
DBS for epilepsy is off-label in children, and most of the controlled evidence comes from adults.
Evidence in children
- First systematic review (40 children, ages 4–18): 85% had fewer seizures, and 12.5% became seizure-free. CM (18 children) and ANT (8) were the commonest targets .
- Meta-analysis (19 studies, 149 children, follow-up at least 12 months):
- The responder rate (at least 50% fewer seizures) was 63.3%, and 13.8% became seizure-free.
- By target: CM 66.2%, ANT 46.2% and CM plus ANT 51.1%. The differences were not significant.
- Age at implantation did not predict response.
- Adverse events occurred in 16.5% (major 10.8%), with no procedure-related deaths .
- Surgical safety (CHILD-DBS registry): major complications occurred in 4.3% of children implanted for epilepsy, vs 15.6% for movement disorders .
Choosing a target
- ANT: experts consider the best candidates to be patients with temporal or frontal seizures refractory to at least two medicines .
- CM: generalized seizure types and LGS.
- Stimulation helped generalized tonic–clonic seizures and atypical absences, but not complex partial seizures .
- Pulvinar: temporal-lobe and posterior networks.
- In adults with simultaneous thalamic recordings, the pulvinar was involved in seizures in all patients and was involved first in 82%.
- In hippocampal or amygdalar onset seizures, 62% involved the pulvinar first vs 31% the ANT .
- Thalamic responsive neurostimulation (RNS) is an alternative:
- In an individual-patient meta-analysis (median age 17), median seizure reduction was 73% .
- In 13 children and young adults (11 CM, 2 ANT), 46% were responders. Those with focal cortical dysplasia did especially well .
Anterior nucleus (ANT)
- Adult evidence:
- SANTÉ randomized trial (110 adults): at the end of the blinded phase, seizures fell by a median 40.4% with stimulation vs 14.5% without. By 2 years the median reduction was 56%, and 54% were responders .
- SANTÉ long-term: median reduction was 75% at 7 years .
- MORE registry (real-world practice): reductions were 33.1% at 2 years and 55.1% at 5 years. High-volume centers did better .
- Side effects: depression and memory complaints were reported more with stimulation .
- Children: 46.2% responders in the pediatric meta-analysis .
Targeting the ANT
- Aim for the anteroventral ANT at the junction with the mammillothalamic tract (MTT):
- In a meta-analysis of 162 patients, responders' active contacts were 1.6 mm more anterior than non-responders', next to the MTT .
- Contacts were about 30% closer to the ANT–MTT junction in responders, and heat maps showed a hot spot there .
- A "highly encouraging location" lay in the anterior and inferior anteroventral nucleus, just medial to the end of the MTT .
- Lead placement matters: in SANTÉ, subjects with good bilateral placement above the ANT–MTT junction were responders more often (43.5% vs 21.9%) .
- Imaging: the ANT is hard to see on standard MRI. FGATIR shows the MTT, whose termination marks the ANT for direct targeting .
- Trajectory:
- Transventricular trajectories put at least one contact in the target region bilaterally in 84% of patients, vs 58% for extraventricular trajectories. No bleeds occurred, and there was 1 cortical infarct with an extraventricular approach .
- Most surgeons use a transventricular approach .
- Programming: most mimic SANTÉ settings but start at a lower amplitude (2–3 V or mA rather than 5 V). Adjustments are mainly driven by mood, memory or paresthesia side effects .
Centromedian nucleus (CM)
- Randomized evidence (ESTEL, 20 young adults with LGS, aged 17–37):
- 50% of the stimulated group had at least 50% fewer diary-recorded seizures vs 22% of controls (not significant).
- Electrographic seizures fell by at least 50% in 59% vs none of the controls .
- LGS overall (individual-patient data, 47 patients, mean age 17.4): 80.9% had at least 50% fewer seizures, 6.4% became seizure-free and quality of life improved in 88.2%. The complication rate was 4.9% .
- Children:
- Single center: 4 of 6 children with LGS (ages 6–19) had more than 60% fewer seizures .
- CHILD-DBS (22 children, ages 5–18):
- 10 had at least 50% fewer seizures, and 73% had less severe seizures.
- Quality of life improved only in those whose seizure frequency fell.
- School attendance rose at 1 year .
Targeting the CM
- See it directly: on 3T MP2RAGE, CM appears bright against the darker pulvinar, mediodorsal and parafascicular nuclei. This allowed accurate targeting in the ESTEL trial .
- Sweet spot: the anterior, inferior and lateral ("parvocellular") border of CM, extending into the ventral lateral and ventral posteromedial nuclei .
- The mean peak MNI coordinate was x −12.9, y −17.2, z +0.9 (left side) .
- Benefit was linked to connectivity with premotor and prefrontal cortex, putamen and pontine brainstem .
- Microelectrode recording: at the group level, CM showed lower firing and background noise than the ventral lateral nucleus. This difference did not hold in 20–25% of individual trajectories, which limits MER's value .
- Electrophysiological confirmation:
- Classic CM targeting used cortical recruiting responses to low-frequency stimulation and EEG desynchronization with high-frequency stimulation.
- Outcomes were better when placement was confirmed than when the target was missed bilaterally .
- In children: frame-based placement used a combination of direct and indirect targeting .
Medial pulvinar
- Early evidence (adults and adolescents):
- During SEEG, high-frequency stimulation of the medial pulvinar made hippocampal seizures less severe in 5 of 8 patients, particularly by preserving consciousness .
- With chronic bilateral medial-pulvinar DBS, 2 of 6 patients were responders. SEEG entropy measures of the medial pulvinar were higher in responders .
- Pulvinar RNS: in 4 patients, including 2 with an LGS phenotype aged 13 and 21, disabling seizures fell by 25%, 50%, 71% and 100% .
- Rationale: the medial pulvinar connects to the temporal lobe, possibly through the temporopulvinar bundle of Arnold .
Targeting the pulvinar
- Target the medial pulvinar .
- Trajectory: in the pulvinar RNS series, leads were placed robotically from a superior parietal or frontal entry, on a trajectory lateral to the ventricles rather than through them .
- Use SEEG first: sampling the medial pulvinar during SEEG has been proposed to guide lead placement and predict response .
Related topics
- Responsive Neurostimulation: the closed-loop thalamic and cortical alternative.
- Lennox–Gastaut Syndrome: CM stimulation and other options in LGS.
- Intracranial EEG: SEEG used to define targets.
- Corpus Callosotomy: the palliative disconnection option.
- Epilepsy Surgery Overview: the wider surgical context.
- Thalamic Deep Brain Stimulation for Epilepsy: Procedure: step-by-step procedure.
References
- Yan H, Toyota E, Anderson M, et al. A systematic review of deep brain stimulation for the treatment of drug-resistant epilepsy in childhood. J Neurosurg Pediatr 2019;23(3):274–284. doi:10.3171/2018.9.PEDS18417. PMID 30544364. verified
- Mhanna A, Ciliberto MA, Ganganna ST, et al. Deep brain stimulation outcomes in pediatric drug-resistant epilepsy: a systematic review and meta-analysis. Seizure 2026;142:281–289. doi:10.1016/j.seizure.2026.09.009. PMID 42767129. verified
- Balachandar A, Verhey LH, Mithani K, et al. Surgical complications of deep brain stimulation in children across targets and indications: multicenter analysis of the CHILD-DBS registry. Neurology 2025;105(9):e214201. doi:10.1212/WNL.0000000000214201. PMID 41071966. verified
- Fasano A, Eliashiv D, Herman ST, et al. Experience and consensus on stimulation of the anterior nucleus of thalamus for epilepsy. Epilepsia 2021;62(12):2883–2898. doi:10.1111/epi.17094. PMID 34697794. verified
- Velasco F, Velasco M, Jiménez F, et al. Predictors in the treatment of difficult-to-control seizures by electrical stimulation of the centromedian thalamic nucleus. Neurosurgery 2000;47(2):295–304. doi:10.1097/00006123-200008000-00007. PMID 10942002. verified
- McGinn R, Von Stein EL, Datta A, et al. Ictal involvement of the pulvinar and the anterior nucleus of the thalamus in patients with refractory epilepsy. Neurology 2024;103(11):e210039. doi:10.1212/WNL.0000000000210039. PMID 39531602. verified
- Bystrom LL, Levy AS, Brown EC, et al. Thalamic responsive neurostimulation for the treatment of refractory epilepsy: an individual patient data meta-analysis. J Neurosurg Pediatr 2023;32(3):366–375. doi:10.3171/2023.5.PEDS22559. PMID 37347644. verified
- Mohanty D, Houck KM, Trandafir C, et al. Responsive neurostimulation of thalamic nuclei for regional and multifocal drug-resistant epilepsy in children and young adults. J Neurosurg Pediatr 2024;34(1):40–48. doi:10.3171/2024.2.PEDS23531. PMID 38608307. verified
- Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia 2010;51(5):899–908. doi:10.1111/j.1528-1167.2010.02536.x. PMID 20331461. verified
- Salanova V, Sperling MR, Gross RE, et al. The SANTÉ study at 10 years of follow-up: effectiveness, safety, and sudden unexpected death in epilepsy. Epilepsia 2021;62(6):1306–1317. doi:10.1111/epi.16895. PMID 33830503. verified
- Peltola J, Colon AJ, Pimentel J, et al. Deep brain stimulation of the anterior nucleus of the thalamus in drug-resistant epilepsy in the MORE multicenter patient registry. Neurology 2023;100(18):e1852–e1865. doi:10.1212/WNL.0000000000206887. PMID 36927882. verified
- Ilyas A, Snyder KM, Thomas TM, et al. Optimal targeting of the anterior nucleus of the thalamus for epilepsy: a meta-analysis. J Neurosurg 2022;137(6):1582–1590. doi:10.3171/2022.2.JNS212550. PMID 35395631. verified
- Schaper FLWVJ, Plantinga BR, Colon AJ, et al. Deep brain stimulation in epilepsy: a role for modulation of the mammillothalamic tract in seizure control? Neurosurgery 2020;87(3):602–610. doi:10.1093/neuros/nyaa141. PMID 32421806. verified
- Costa-Gertrudes R, Simão D, Franco A, et al. Anterior nucleus of thalamus deep brain stimulation: a clinical-based analysis of the ideal target in drug-resistant epilepsy. Stereotact Funct Neurosurg 2022;100(2):108–120. doi:10.1159/000519917. PMID 34915532. verified
- Gross RE, Fisher RS, Sperling MR, et al. Analysis of deep brain stimulation lead targeting in the Stimulation of Anterior Nucleus of the Thalamus for Epilepsy clinical trial. Neurosurgery 2021;89(3):406–412. doi:10.1093/neuros/nyab186. PMID 34161589. verified
- Grewal SS, Middlebrooks EH, Kaufmann TJ, et al. Fast gray matter acquisition T1 inversion recovery MRI to delineate the mammillothalamic tract for preoperative direct targeting of the anterior nucleus of the thalamus for deep brain stimulation in epilepsy. Neurosurg Focus 2018;45(2):E6. doi:10.3171/2018.4.FOCUS18147. PMID 30064328. verified
- Lehtimäki K, Coenen VA, Gonçalves Ferreira A, et al. The surgical approach to the anterior nucleus of thalamus in patients with refractory epilepsy: experience from the international multicenter registry (MORE). Neurosurgery 2019;84(1):141–150. doi:10.1093/neuros/nyy023. PMID 29554309. verified
- Dalic LJ, Warren AEL, Bulluss KJ, et al. DBS of thalamic centromedian nucleus for Lennox-Gastaut syndrome (ESTEL trial). Ann Neurol 2022;91(2):253–267. doi:10.1002/ana.26280. PMID 34877694. verified
- Shlobin NA, Hofmann K, Cohen NT, et al. Deep brain stimulation of the centromedian nucleus of the thalamus for Lennox-Gastaut syndrome: a systematic review and individual patient data analysis. Neurosurgery 2023;92(4):703–715. doi:10.1227/neu.0000000000002280. PMID 36700706. verified
- Bonda D, Kelly KA, Boop S, et al. Deep brain stimulation of bilateral centromedian thalamic nuclei in pediatric patients with Lennox-Gastaut syndrome: an institutional experience. World Neurosurg 2024;185:e631–e639. doi:10.1016/j.wneu.2024.02.099. PMID 38403017. verified
- Mithani K, Niazi F, Suresh H, et al. Deep brain stimulation of the centromedian nucleus for drug-resistant epilepsy in children: quality-of-life and functional outcomes from the CHILD-DBS registry. Epilepsia 2025;66(7):2225–2238. doi:10.1111/epi.18393. PMID 40167366. Full text (PMC) verified
- Warren AEL, Dalic LJ, Thevathasan W, et al. Targeting the centromedian thalamic nucleus for deep brain stimulation. J Neurol Neurosurg Psychiatry 2020;91(4):339–349. doi:10.1136/jnnp-2019-322030. PMID 31980515. verified
- Warren AEL, Dalic LJ, Bulluss KJ, et al. The optimal target and connectivity for deep brain stimulation in Lennox-Gastaut syndrome. Ann Neurol 2022;92(1):61–74. doi:10.1002/ana.26368. PMID 35429045. Full text (PMC) verified
- Filipescu C, Lagarde S, Lambert I, et al. The effect of medial pulvinar stimulation on temporal lobe seizures. Epilepsia 2019;60(4):e25–e30. doi:10.1111/epi.14677. PMID 30767195. verified
- Bratu IF, Carron R, Clement A, et al. Medial pulvinar stereoelectroencephalographic biomarkers associated with deep brain stimulation response in focal drug-resistant epilepsy. Epilepsia 2026;67(1):e8–e17. doi:10.1111/epi.70046. PMID 41342095. verified
- Wang R, Sacknovitz A, Vazquez S, et al. Bilateral pulvinar responsive neurostimulation for bilateral multifocal posteriorly dominant drug resistant epilepsy. Epilepsia Open 2024;9(6):2263–2273. doi:10.1002/epi4.13068. PMID 39435755. Full text (PMC) verified
- Kalamatianos T, Mavrovounis G, Skouras P, et al. Medial pulvinar stimulation in temporal lobe epilepsy: a literature review and a hypothesis based on neuroanatomical findings. Cureus 2023;15(3):e35772. doi:10.7759/cureus.35772. PMID 37025746. verified
Verification (2026-11-02): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed, and every figure cited was checked against the PubMed abstract. The CM sweet-spot MNI coordinates were taken from the full text of reference 23 (Table 2), the pediatric age range and targeting method from the full text of reference 21, and the pulvinar trajectory from the full text of reference 26, all on PMC. References 4–6, 9–17, 22–25 and 27 are adult or mixed-age; reference 18 enrolled young adults aged 17–37. Reference 27 is a hypothesis-generating review. Indirect AC–PC coordinates for ANT, CM and pulvinar are not given because they could not be verified from accessible sources. The ANT "highly encouraging location" MNI box in reference 14 is described in words rather than numbers. The schematic is an original figure.